Applications of Ifosfamide in Industrial Manufacturing

As a specialized manufacturer of Ifosfamide, we supply this key active pharmaceutical ingredient (API) to established sectors with rigorous regulatory requirements. The following application scenarios reflect the real-world downstream use of Ifosfamide, addressing industrial compliance, controlled formulation, integration in precise process steps, and typical end product forms.

1. Oncology Pharmaceutical Formulation

Ifosfamide is a critical cytotoxic alkylating agent employed in the large-scale manufacture of injectable anti-cancer medications, specifically indicated for advanced testicular cancer and select solid tumors. Major pharmaceutical companies utilize it as an API under stringent GMP guidelines and global pharmacopoeial standards, where dosage form developers determine optimal concentration based on target patient population, tumor type, and formulation stability findings. It integrates into aqueous solution compounding following sterilization steps and precise dissolution protocols in validated cleanrooms; the output, after filtration and aseptic filling, is injectable chemotherapy vials provided to hospital pharmacies and oncology clinics.

Industry compliance standards

• ICH Q7 GMP for Active Pharmaceutical Ingredients
• US Pharmacopeia (USP) Monograph for Ifosfamide
• European Pharmacopoeia (Ph. Eur.) 10.0
• Japanese Pharmacopoeia (JP XVIII)
• 21 CFR Part 211 FDA cGMP for Finished Pharmaceuticals

Typical usage ratio

• Dosage forms typically contain Ifosfamide at 1–3 grams per vial, with batch concentration calculated based on individual pharmaceutical company formulation requirements and titration against shelf-life data and reconstitution properties.

Downstream process integration

• Ifosfamide dissolves in sterile water within segregated class 100 cleanroom reactors following raw material identity and purity verification. The compound proceeds through critical solution compounding, filtration, sterile filling, lyophilization (if required), and capping as part of the injectable production line.

Final product types

• Lyophilized injectable vials for hospital oncology use
• Ready-to-use cytostatic solution ampoules
• Infusion bag preparations for chemotherapy protocols

2. Active Substance Supply for Generic Drug Manufacturing

Generic drug manufacturers secure Ifosfamide API as the central component in replicating branded formulations for approved oncology indications post-patent expiry. These companies conduct precise QC to match the reference listed drug in both composition and bioperformance, working under regional drug authority guidelines specific to generics. The API integrates after solid and solution formulation steps and stability assessment, with automated filling technologies ensuring consistent dosing and effective batch tracking for pharmacovigilance.

Industry compliance standards

• WHO Prequalification Programme for Active Pharmaceutical Ingredients
• Good Manufacturing Practice (PIC/S Guide PE 009)
• Schedule M of Drugs and Cosmetics Rules, India (if producing in India)
• Relevant regional bioequivalence guidelines (EMA, FDA, NMPA, etc.)

Typical usage ratio

• The API concentration per finished unit aligns with bioequivalence to originator – typically 1 g or 2 g per vial. Adjustment depends on pharmacopeial bulk assay outcomes, excipient compatibility, and in-process validation results.

Downstream process integration

• After in-house or third-party release testing, the API enters weighed batching and is combined with sterile diluents and excipients in controlled temperature vessels. Final dosage validation and fill-finish automation follow stability pilot runs.

Final product types

• Single-use injectables mimicking branded reference oncology medicines
• Oncology combination therapy packs supplied to treatment centers

3. Bulk Supply for Hospital Pharmacy Compounding

Hospital compounding centers rely on industrial-grade Ifosfamide supplied in bulk to formulate custom doses for chemotherapy protocols not available in pre-filled vials, including patient-specific therapies or off-label regimens. Compliance with hospital compounding regulations dictates traceability from manufacturer to compounding bench, while strict inventory control and quality assurance minimize contamination risk. Bulk material enters solution compounding and aliquoting workflows, supporting swift response to oncologist requests.

Industry compliance standards

• USP General Chapter <797> Pharmaceutical Compounding – Sterile Preparations
• Guidelines for Compounding Sterile Preparations by ASHP
• Compliance with The Joint Commission (TJC) Medication Management standards
• State FDA and national health authority controls for drug sourcing and compounding

Typical usage ratio

• Bulk Ifosfamide is typically reconstituted to 50 mg/mL or 100 mg/mL solution strength, adjusted according to physician order and compounding protocol, with strict upper limits per administration episode as controlled by national pharmacy guidelines.

Downstream process integration

• Bulk API undergoes incoming QC, then transfers to Class A cleanroom hoods for manual or semi-automated serial dilution, aliquoting into syringes or infusion bags using single-use sterile devices, with traceable lot/batch control on all outputs.

Final product types

• Personalized dose syringes for patient therapy
• Compounded infusion bags for clinic and inpatient chemotherapy suites
• Stock solutions for multi-patient daily chemotherapy cycles

4. Cytotoxic Drug Manufacturing for Clinical Trials

Pharmaceutical research contractors and R&D centers purchase Ifosfamide in GMP-certified lots for use in clinical trial material (CTM) preparation, addressing the specific dosing and regulatory dossier demands of early-phase oncology studies. Here, traceability from API batch through each clinical trial participant’s dosing event is mandatory, with full documentation for regulatory inspections. Downstream, the API enters formulation development, pilot-scale filling, stability testing, and packaging processes, ensuring consistency for both blinded and open-label trial arms.

Industry compliance standards

• ICH Q7, Q8 and Q9 guidance for investigational medicinal products
• Good Clinical Practice (GCP) E6(R2)
• EU Regulation (EU) No 536/2014 on clinical trials
• FDA Guidance for Industry: CGMP for Phase 1 Investigational Drugs

Typical usage ratio

• Dosing in trial kits varies from 500 mg/vial to 4 g/vial—defined by study protocol, pharmacokinetic modeling, and lab-scale compounding method validations, with overages calculated for stability and handling losses in clinical sites.

Downstream process integration

• Manufactured lots, kept under chain-of-custody, are portioned in trial kit assembly cleanrooms, with API introduced at formulation or sterile filling stages, preceding randomized packaging and clinical labeling according to the trial’s blinding requirements.

Final product types

• Clinical trial investigational vials for oncology drug research
• Patient-ready dosing kits for hospital and ambulatory clinical trial sites
• Reference and stability control samples for trial monitoring laboratories